ArticleJournal of the American Academy of Dermatology2020

Bullous disorders associated with PD-1 and PD-L1 inhibitors: Pharmacovigilance analysis of the United States Food and Drug Administration Adverse Event Reporting System from the Research on Adverse Drug Events And Reports Program.

Javier Jimenez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.